In an effort to design dinuclear Pt II compounds that maintain the target (DNA) binding profile of the trans-oriented dinuclear bifunctional Pt II complexes containing aliphatic linker chains but are less susceptible to metabolic decomposition, the new, longchain dinuclear Pt II complexes-[{trans-PtCl(dien)} 2 -μ-(CH 2 ) n ] 2+ (n = 7,10,12, dien = diethylenetriamine)-were synthesized. The toxicity of these metallodrugs was examined in ovarian tumor cell lines. The results showed that the activity of these complexes increased with growing length of the linker; the activity of complex containing the longest linker (n = 12) was comparable with that of cis-diamminedichloridoplatinum(II) (cisplatin). This observation correlated with the results of DNA binding studies performed in cell-free media.
INTRODUCTION
Polynuclear complexes represent a distinct class of Pt-based anticancer agents that contain two or more Pt centers linked by a chain of different length [1, 2] . DNA binding, and the consequences for structure and function, is the mechanistic paradigm by which cytotoxic Pt complexes are believed to exert their antitumor activity [3] [4] [5] . Thus, antitumor polynuclear Pt complexes were designed as a result of systematically testing the hypothesis that Pt drugs that bind to DNA in a manner fundamentally different from that of the conventional mononuclear cis-diamminedichloridoplatinum(II) (cisplatin) and its analogues, can exhibit altered biological properties including the spectrum and intensity of antitumor activity [6, 7] . The chemistry and biological activity of polynuclear Pt complexes may be modulated by the geometry and number of leaving groups in the coordination sphere as well as by the nature of the chain linking the Pt centers [1, 2, 8, 9] .
Initial studies on polynuclear Pt antitumor drugs focused on symmetric dinuclear bifunctional Pt II complexes where the two Pt atoms have equivalent coordination spheres, represented by the general formula [{trans-PtCl(NH 3 ) 2 } 2 -μ-NH 2 (CH 2 ) n NH 2 ] 2+ , n = 2-6 (1,1/t,t-n, Fig. 1 ) [10] . The properties of these formally bifunctional complexes have been reported including their different spectrum of cytostatic activity and activity in tumor cells resistant to conventional cisplatin [11] [12] [13] [14] . In addition, several papers have demonstrated unique DNA binding modes of these bifunctional dinuclear Pt II compounds [10, [15] [16] [17] [18] [19] . For instance, they preferentially form so called long-range cross-links (CLs) in which the platinated sites in DNA are separated by one or more base pairs. Moreover, in contrast to cisplatin, which forms on DNA ~90 % intrastrand CLs and only 6 % interstrand CLs [21] , these dinuclear bifunctional Pt II compounds form on DNA ~80 % interstrand CLs [20] . Also, as a consequence of the global (random) modification of natural, high-molecular-mass DNA by these dinuclear bifunctional Pt II compounds, the conformation of this target biomacromolecule is altered in a way that is distinctly different from the modifications by cisplatin [10, 17] . As might be expected, varying the length of the linker may affect the distance and spatial configuration of the reactive chloride groups in these dinuclear compounds, hence also their DNA binding mode and consequently biological effect. However, no systematic study of the effect of the length of the linker has been performed in particular for the complexes containing longer aliphatic linker chains such as in 1,1/t,t-n > 6.
Pt center and the linker and liberation of the terminal amine of the alkane diamine linker [22, 23] . Hence, this metabolic effect is likely to be highly deactivating and also results in loss of the capacity to form long-range CLs responsible for unique biological properties of dinuclear bifunctional Pt II complexes.
In an effort to design dinuclear Pt II compounds that maintain the target (DNA) binding profile of the "parent" compounds 1,1/t,t-n but are less susceptible to metabolic decomposition, the new, long-chain bifunctional dinuclear Pt II complexes structurally cognate with the latter dinuclear complex-[{trans-PtCl(dien)} 2 -μ-(CH 2 ) n ] 2+ (1,1/t,t(dien)-n, n = 7,10,12 and dien = diethylenetriamine, Fig. 1 )-were synthesized. Importantly, preliminary results showed that there was no breakage of the linker groups of these new dinuclear Pt II complexes in the presence of S-containing species at physiological pH. In addition, the preliminary results also revealed that DNA binding mode of the new dinuclear Pt II compounds was dependent on the length of the linker. Therefore, we examined in the present work toxicity of 1,1/t,t(dien)-n (n = 7,10,12) in two tumor cell lines, cisplatin-sensitive A2780 and isogenic multifactorial-resistant A2780cisR, respectively. Attention was paid to the comparison of the effect of these longer aliphatic linkers on cytotoxicity and DNA-binding modes of these metallodrugs in a cell-free medium. Reactivity of 1,1/t,t(dien)-n compounds with glutathione (GSH), which has been chosen for investigation in this study because of its role as a determinant of cellular sensitivity to a wide variety of drugs and cytotoxic agents, was investigated as well.
RESULTS AND DISCUSSION

Cytotoxicity
The cytotoxic activity of 1,1/t,t(dien)-n (n = 7,10,12) and cisplatin was determined against human ovarian carcinoma cell lines A2780 (parent cisplatin-sensitive) and A2780cisR (acquired resistance to cisplatin) commonly used to test cytotoxic activity of cisplatin analogues and other antitumor metallodrugs. The cell lines were incubated for 72 h with the Pt compound, and the cell survival in the culture treated with the Pt compound was evaluated as described in the Supplementary Information. The three dinuclear Pt II compounds showed activity in the tested concentration range, and their corresponding IC 50 values are reported in Table 1 . In general, the activity of complexes 1,1/t,t(dien)-n (n = 7,10,12) increased with growing length of the linker in both cell lines. Interestingly, the activity of complex containing the longest linker (n = 12) was comparable with that of cisplatin in both cell lines. This observation suggests that the mechanism underlying the biological action of the new dinuclear Pt II complexes tested in the present work does not allow these complexes to overcome resistance mechanisms developed by cells against cisplatin. On the other hand, the experiments performed in cellulo strongly support the thesis that toxicity of long-chain dinuclear bifunctional trans-Pt II complexes in tumor cells increases with the growing length of the aliphatic bridge linking Pt II centers. [20] . e Ref. [31] .
DNA binding in cell-free media
One of the important early phases of the mechanism by which Pt compounds exert their anticancer activity is formation of adducts on nuclear DNA by these agents [24] [25] [26] . Hence, the ability of Pt complexes to coordinatively bind DNA and the rate of this binding are of great interest.
The first experiments were aimed at quantifying the binding of 1,1/t,t(dien)-n (n = 7,10,12) to mammalian DNA. Solutions of double-helical calf thymus (CT) DNA at a concentration of 32 μg mL -1 were incubated with the dinuclear Pt II complexes at r i = 0.08 in NaClO 4 (10 mM) at 37 °C. At various time intervals, aliquots of the reaction mixture were withdrawn and assayed for Pt complex bound to DNA. The amount of complexes bound to DNA increased with time, and all dinuclear Pt II complexes were quantitatively bound after 6 h. The times at which the binding of 1,1/t,t(dien)-n complexes reached 50 % (t 50% ) were 16 ± 1, 15 ± 1, and 13 ± 1 min for n = 7,10,12, respectively. These results indicate that the rate of binding of the dinuclear Pt II complexes tested in the present work to natural double-helical DNA is considerably higher than that of cisplatin (t 50% = ca. 120 min [27] ). It implies that the somewhat reduced biological activity of 1,1/t,t(dien)-n (n = 7,10) in A2780 and A2780cisR cells is not due to an inherently slower rate of initial binding of these dinuclear Pt II complexes to DNA.
One of the limiting factors that determine the cytotoxicity of Pt compounds is the nature of the conformational changes induced in DNA. Hence, data on DNA binding mode of Pt complexes are of great interest. In order to determine the character of DNA adducts of 1,1/t,t(dien)-n (n = 7,10,12) and structural characteristics of damaged DNA, several biochemical and biophysical methods have been applied. For these analyses, samples of DNA modified by 1,1/t,t(dien)-n (n = 7,10,12) at a preselected value of r b (r b is defined as the number of molecules of the Pt complex bound per nucleotide residue) prepared as described in the Experimental section were used. Thus, the analyses described below were performed in the absence of unbound (free) Pt complex.
In vitro RNA synthesis by T7 RNA polymerase on DNA templates [pSP73KB plasmid (2455 bp) linearized by NdeI restriction endonuclease] containing adducts of 1,1/t,t(dien)-n (n = 7,10,12) revealed (Fig. 2) that the major stop sites produced by these complexes were mainly at guanine residues. This result also suggests that the adducts formed by the dinuclear Pt II complexes tested in the present work are able to inhibit RNA polymerase. Importantly, the sequence dependence of the inhibition of RNA synthesis by the adducts of 1,1/t,t(dien)-n was identical for all three dinuclear Pt II complexes and was J. PRACHAROVA et al.
considerably less regular than that by the adducts of cisplatin. The latter results indicate that the dinuclear Pt II compounds tested in the present work form a greater variety of adducts with DNA and less regularly than cisplatin.
Bifunctional Pt compounds that covalently bind to DNA form various types of interstrand and intrastrand CLs. Considerable evidence suggests that the antitumor efficacy of bifunctional Pt compounds is the result of the formation of these lesions, but their relative efficacy remains unknown. We quantified the interstrand cross-linking efficiency of 1,1/t,t(dien)-n (n = 7,10,12) in pSP73KB plasmid linearized by EcoRI by gel electrophoresis under denaturing conditions [11] (Fig. 3) . The interstrand cross-linking efficiencies (defined as the number of interstrand CLs per one adduct of the Pt complex [11] of 1,1/t,t(dien)-n complexes reached) were 56 ± 2, 72 ± 3, and 91 ± 3 % for n = 7,10,12, respectively. These results indicate that DNA interstrand cross-linking efficiency of 1,1/t,t(dien)-n (n = 7,10,12) increased with growing length of the linker. In addition, these results demonstrate that the most prevalent adducts formed in double-helical DNA by these dinuclear Pt II complexes are interstrand CLs, which is in contrast to mononuclear cisplatin, which forms only 6 % interstrand CLs [20] , and its major adducts are intrastrand CLs between neighboring base residues [21] . Antitumor dinuclear trans-Pt II complexes 347 Binding of ethidium bromide (EtBr) to DNA by intercalation is blocked in a stoichiometric manner by formation of the bifunctional adducts of a series of Pt complexes including cisplatin, which results in a loss of fluorescence intensity. Modification of DNA by 1,1/t,t(dien)-n (n = 7,10,12) or cisplatin resulted in a decrease of EtBr fluorescence (Fig. 4) . The decrease caused by the adducts of the dinuclear Pt II complexes tested in the present work was markedly more pronounced than that induced by the DNA adducts of cisplatin at equivalent r b values. In addition, this effect on EtBr fluorescence increased with the growing length of the aliphatic bridge linking Pt II centers. The results of these experiments (Fig. 4) suggest that the conformational distortion induced in DNA by the adducts of 1,1/t,t(dien)-n (n = 7,10,12) extends over a markedly higher number of base pairs around the platination sites as in the case of the adducts of cisplatin. A plausible explanation of the distinct behavior of DNA adducts of the dinuclear Pt II complexes tested in the present work (Fig. 4) is that these complexes preferentially form long-range CLs similarly as other di/trinuclear Pt II complexes do [9, 18, 19, [28] [29] [30] .
Circular dichroism (CD) spectral characteristics for CT DNA modified by 1,1/t,t(dien)-n (n = 7,10,12) to values of r b in the range 0.025-0.3 (Fig. 5) were determined. Upon binding of these compounds to CT DNA, the conservative CD spectra normally found for DNA in the canonical B-conformation considerably transform at wavelengths below 300 nm. There was a slight increase in the intensity of the positive band around 280 nm if DNA was modified at relatively lower values of r b (Fig. 5) . At higher levels of the modification (r b > ~0.6), the intensity of this CD band began to decrease, this effect increased with the growing length of the aliphatic bridge linking Pt II centers. Thus, the dinuclear Pt II complexes tested in the present work affected the CD spectra of CT DNA in a way similar to cisplatin under identical conditions [31] . We interpreted CD spectra of DNA modified by the dinuclear Pt II complexes on the basis of the analogy with the changes in the CD spectra of DNA modified by cisplatin and clinically ineffective transplatin [31] . It might be suggested that the binding of 1,1/t,t(dien)-n (n = 7,10,12) affects the DNA conformation such that the character of the conformational changes induced in DNA corresponds at lower levels of DNA platination to nondenaturational conformational alterations. At higher levels of DNA platination, the character of the conformational changes induced in DNA corresponds rather to denaturational alterations [31] . Analysis of DNA modified by 1,1/t,t(dien)-n (n = 7,10,12) also revealed that efficiency of these dinuclear Pt II complexes to affect DNA conformation increased with the growing length of the aliphatic bridge linking Pt II centers. Mammalian CT DNA was modified by 1,1/t,t(dien)-n (n = 7,10,12) to various r b values and melting curves were recorded in the medium of a relatively high ionic strength containing 0.1 M Na + (Fig. 6) . The effect on melting temperature (t m ) was dependent on the amount of Pt complex bound (Fig. 6) . The modification of DNA by the dinuclear Pt II complexes at lower r b values (up to r b~0 .08) resulted in a slight increase of t m . In contrast, at higher levels of the modification, t m began to decrease. This decrease of t m was most pronounced for the dinuclear Pt II complex containing the longest aliphatic bridge linking Pt II centers (n = 12). Antitumor dinuclear trans-Pt II complexes 349 Previously, three major factors have been invoked to account for the thermal stability of DNA modified by Pt II complexes capable of DNA cross-linking and the observed change in t m of DNA as a consequence of its platination reflects the relative proportion and contribution of these three factors [32] . These major factors are (i) a destabilizing effect of conformational distortions due to the formation of CLs induced in DNA by Pt coordination; (ii) stabilizing effects of DNA interstrand CLs, which prevent dissociation of DNA strands; (iii) the positive charge on the Pt II centers (introduction of a positive charge into the DNA molecule, e.g., by binding of positively charged ligands such as Pt II moieties of Pt antitumor compounds, results in a stabilization of the DNA duplex by decreasing electrostatic repulsion of negative charges of phosphate groups located at the complementary strands). However, it has been shown [33] that cations present in the medium also stabilize DNA against thermal denaturation by decreasing electrostatic repulsion of negative charges of phosphate groups located at the complementary strands. Hence, the stabilization effect of the positive charge on the Pt II centers practically disappears at sufficiently high concentrations of the cations. Thus, at high ionic strength (0.1 M Na + ) when the electrostatic stabilizing effects of the dinuclear Pt II complexes tested in the present work are markedly weakened, the value of t m is affected by destabilizing effects of conformational distortions induced by lesions of the Pt complexes and the stabilizing effects of interstrand CLs.
Therefore, the observation that the t m values of DNA modified by 1,1/t,t(dien)-n (n = 7,10,12) considerably decreased at higher r b values is consistent with the occurrence of conformational alterations induced in DNA by these complexes, which destabilize the duplex. In other words, at higher Na + concentrations, destabilization of DNA resulting from conformational distortions induced by 1,1/t,t(dien)-n (n = 7,10,12) overcompensates the stabilization effects of DNA interstrand CLs. Interestingly, the decrease of t m values observed at higher r b values increased with the growing length of the aliphatic bridge linking Pt II centers (Fig. 6 ) with the concomitant increase of the interstrand crosslinking efficiency (vide supra). Hence, the results of DNA melting experiments are consistent with the thesis that the growing length of the aliphatic bridge linking Pt II centers promotes more distorting conformational alterations induced in DNA by the dinuclear Pt II complexes tested in the present work.
Reactions with reduced glutathione
Pt II compounds have a strong thermodynamic preference for binding to S-donor ligands, such as thiolates [34, 35] ; hence, before Pt II drugs reach the DNA in the nucleus of tumor cells, or even after they bind to DNA, they may still react with various compounds including S-containing molecules [36, 37] . These reactions are generally believed to play a role in mechanisms underlying tumor resistance to Pt compounds, their inactivation, and side effects. Therefore, interest in the interactions of Pt antitumor drugs with S-containing molecules of biological significance has recently markedly increased [37] .
In the present work, we investigated, using UV absorption spectrophotometry, irreversible binding of GSH with 1,1/t,t(dien)-7 in comparison with 1,1/t,t-6 following exactly the procedure outlined by Dabrowiak et al. [38] . The dinuclear Pt II complexes at a concentration of 32 μM were incubated with 16 mM GSH (these concentrations of Pt complex and GSH and the ratio of thiol to drug (500:1) represent the physiologically relevant values [38] ) at 37 °C in 4.6 mM NaCl plus 100 mM NaClO 4 pH 6.0 as described in the Supplementary Information. Figure 7 shows UV absorption (at 260 nm) of the Pt complexes and GSH as a function of time, with the absorptions of GSH and Pt complex alone subtracted. The t 1/2 (half-times of the reactions, which mainly result in the formation of Pt-S bonds) were 81.8 ± 1.2 for 1,1/t,t(dien)-7 (one-phase exponential association) and 64.4 ± 1.5 and 6.4 ± 0.6 min for reaction 1,1/t,t-6 with GSH (two-phase exponential association). Thus, 1,1/t,t(dien)-7 reacted with GSH more slowly than 1,1/t,t-6. Both clinical and preclinical studies have shown that cells with an elevated level of GSH (>10 mM) may be resistant to cisplatin and its analogues [24, [39] [40] [41] . Further studies are warranted to dissect what part of the cytotoxicity of 1,1/t,t(dien)-7 is unfavorably affected by its reaction with GSH.
